Preferential Rights Issue /
Företrädesemission 2020

Alzinova carries out a preferential rights issue of SEK 50 million to further finance the clinical development of ALZ-101. Below you will find information in regards to this issue and the prospectus.

• Read the full prospectus
• Read the “teaser”/short folder
• Application form / Anmälningssedel
• Press release 30 Sep. 2020, start of subscription period:
  – Swedish
  – English
• Press release 29 Sep. 2020, publication of prospectus:
  – Swedish
  – English
• Press release, 18 Sep. 2020:
  – Swedish
  – English
• Link to our financial advisor – Redeye AB
• Interim report Q2, 2020
  – Swedish
  – English
• Annual report 2019:
  – Swedish
  – English
• Annual report 2018, Swedish
• Articles of Association, in Swedish
• Registration certificate Alzinova AB, in Swedish
• Terms and conditions warrants